Unibest Unveils Innovative 505(b)(2) Project for Semaglutide: UB104

In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide. Our latest project, codenamed UB-PEP-104, is set to revolutionize how patients receive this important medication.

The Challenge

Semaglutide, a popular medication for treating type 2 diabetes and obesity, has traditionally been administered via injection. While effective, this method can be inconvenient and uncomfortable for some patients, potentially affecting adherence to treatment regimens.

Our Innovative Solution

Unibest's UB-PEP-104 project tackles this challenge head-on with a novel approach:

1. Additive Manufacturing: We're harnessing the power of 3D printing technology to create a unique oromucosal delivery cavity.

2. Enhanced Bioavailability: Preclinical testing has shown our method achieves greater than 1 relative bioavailability compared to traditional injection.

3. Comparable Efficacy: The new delivery system maintains a similar half-life to injectable Semaglutide.

4. Patient-Centric Design: Our primary goal is to offer a more convenient administration method, potentially improving patient compliance and quality of life.

Comprehensive Semaglutide Services

This innovative project is just one part of Unibest's comprehensive Semaglutide service package, which includes:

• API and intermediates supply

• Generic tablet technology transfer

• Injection licensing and distribution

• 505(b)(2) innovative drug delivery system for co-development: UB-PEP-104

Looking Ahead

As UB-PEP-104 progresses through its preclinical stage, we at Unibest are excited about its potential to transform Semaglutide treatment. This project exemplifies our commitment to leveraging advanced technology and sustainable solutions to address pain points in the drug life cycle.

Read more about Unibest License and NewCo services here.